We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The World Health Organization Prequalification Program and Clinical Pharmacology in 2030.
- Authors
Blaschke, Terrence F.; Lumpkin, Murray; Hartman, Daniel
- Abstract
These procurement agencies and often countries themselves used WHOPQ listing as a resource when selecting product vendors to assure that their funds were buying quality-assured product versions. Any manufacturer is permitted to submit their product dossier to the WHOPQ program for assessment if that product is one in which the relevant WHO medical program has expressed interest for use in LMIC health programs. GLO:1V0/01jan20:cpt1680-fig-0001.jpg PHOTO (COLOR): This figure shows the number of products "listed" (i.e., approved) by the World Health Organization Prequalification (WHOPQ) program as of January 2019 across the four PQ product streams. Ahonkhai I et al i .[3] investigated the product registration ecosystem timelines in 2012, including WHOPQ when required, intended for LMIC diseases, and proposed a framework to reduce product registration time.
- Subjects
CLINICAL pharmacology; INTERNATIONAL organization; WORLD health; EMERGING infectious diseases; PAPILLOMAVIRUS diseases
- Publication
Clinical Pharmacology & Therapeutics, 2020, Vol 107, Issue 1, p68
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.1680